Guangdong Zhongsheng Reports Positive Phase I Results for Innovative Weight Loss Drug RAY1225
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based biopharmaceutical company, has announced promising top-line...
Drug
Jiangsu Hengrui’s Generic Version of Tepadina Approved for Transplantation Conditioning in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...
Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments
Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s...
EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...
FibroGen’s Roxadustat Approved in Macau for Chronic Kidney Disease-Related Anemia
FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it...
Yifan Pharmaceutical’s F-627 Approved by European Commission for Marketing in EU
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary...
Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...
Lynk Pharmaceuticals Doses First Patient in Phase III Trial for Atopic Dermatitis Treatment
Lynk Pharmaceuticals Co., Ltd, based in China, has announced the dosing of the first patient...
HutchMed Launches Phase II/III Study for Sovleplenib in Autoimmune Hemolytic Anemia
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of the Phase II/III...
NeuExcell Therapeutics Doses First Patient in Groundbreaking Clinical Trial for NeuroD1 Gene Therapy
NeuExcell Therapeutics, a Shanghai-based developer of in vivo neural regenerative therapies, has announced the first...
FDA Grants Accelerated Approval for Takeda’s Iclusig in Newly Diagnosed Ph+ ALL
The U.S. Food and Drug Administration (FDA) has granted accelerated indication extension approval to Japan’s...
iRegene’s NouvSight001 Gains Orphan Drug Designation for Retinitis Pigmentosa Treatment
Wuhan-based cell therapy innovator iRegene has secured Orphan Drug Designation (ODD) from the U.S. FDA...
BMS Reports Positive Phase III Results for Opdivo and Yervoy in Advanced HCC
Bristol Myers Squibb (BMS; NYSE: BMY) announced this week that its Phase III study evaluating...
Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors
Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...
CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from...
Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received...